138 related articles for article (PubMed ID: 35874753)
1. Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.
Yi G; Huang Z; Huang Z; Wang Y; Deng W; Zheng S; Li T
Front Immunol; 2022; 13():914265. PubMed ID: 35874753
[TBL] [Abstract][Full Text] [Related]
2. [Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review].
Li GM; Jin YB; Gan YZ; Chen C; Jia Y; Li C
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1208-1213. PubMed ID: 36533357
[TBL] [Abstract][Full Text] [Related]
3. [Systemic lupus erythematosus associated macrophage activation syndrome with neuropsychiatric symptoms: A report of 2 cases].
Luo ZJ; Wu JJ; Song Y; Mei CL; DU R
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):1111-1117. PubMed ID: 38101797
[TBL] [Abstract][Full Text] [Related]
4. Clonal cytophagic histiocytic panniculitis in children may be cured by cyclosporine A.
Bader-Meunier B; Fraitag S; Janssen C; Brochard K; Lamant L; Wouters C; Bodemer C
Pediatrics; 2013 Aug; 132(2):e545-9. PubMed ID: 23858422
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
[TBL] [Abstract][Full Text] [Related]
6. Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels.
Wakiguchi H; Hasegawa S; Hirano R; Kaneyasu H; Wakabayashi-Takahara M; Ohga S
Pediatr Rheumatol Online J; 2015 Nov; 13():49. PubMed ID: 26581448
[TBL] [Abstract][Full Text] [Related]
7. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis.
Karakike E; Giamarellos-Bourboulis EJ
Front Immunol; 2019; 10():55. PubMed ID: 30766533
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still's Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults.
Shiga T; Nozaki Y; Tomita D; Kishimoto K; Hirooka Y; Kinoshita K; Funauchi M; Matsumura I
Front Immunol; 2021; 12():750114. PubMed ID: 34691064
[TBL] [Abstract][Full Text] [Related]
9. [Macrophage activation syndrome revealing subcutaneous T-cell lymphoma in a 16-year old adolescent].
Hbibi M; Benmiloud S; Rahmouni S; Tadmouri I; Abourazzak S; Chaouki S; Souilmi FZ; Idrissi ML; Hida M
Pan Afr Med J; 2018; 31():74. PubMed ID: 31007821
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous panniculitis-like T-cell lymphoma presenting with hemophagocytic lymphohistiocytosis and skin lesions with characteristic high-resolution ultrasonographic findings.
Hung GD; Chen YH; Chen DY; Lan JL
Clin Rheumatol; 2007 May; 26(5):775-8. PubMed ID: 16465478
[TBL] [Abstract][Full Text] [Related]
11. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases.
Lin CI; Yu HH; Lee JH; Wang LC; Lin YT; Yang YH; Chiang BL
Clin Rheumatol; 2012 Aug; 31(8):1223-30. PubMed ID: 22615046
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib for the treatment of atopic dermatitis.
Melo A; Carrascosa JM; Torres T
J Dermatolog Treat; 2022 Aug; 33(5):2404-2413. PubMed ID: 34379541
[TBL] [Abstract][Full Text] [Related]
13. Occult macrophage activation syndrome in systemic-onset juvenile idiopathic arthritic syndrome--a case report.
Zeng P; Li F; Zeng H
Acta Reumatol Port; 2013; 38(3):196-200. PubMed ID: 24149017
[TBL] [Abstract][Full Text] [Related]
14. Panniculitis following baricitinib initiation for treatment of rheumatoid arthritis.
Fike A; Kent R; Biehl A; Ward MM
Joint Bone Spine; 2020 Oct; 87(5):509-510. PubMed ID: 32461123
[No Abstract] [Full Text] [Related]
15. Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A.
Al Zolibani AA; Al Robaee AA; Qureshi MG; Al Nosian H
Skinmed; 2006; 5(4):195-7. PubMed ID: 16855414
[TBL] [Abstract][Full Text] [Related]
16. Macrophage activation syndrome associated with griscelli syndrome type 2: case report and review of literature.
Sefsafi Z; Hasbaoui BE; Kili A; Agadr A; Khattab M
Pan Afr Med J; 2018; 29():75. PubMed ID: 29875956
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous Panniculitis-like T Cell Lymphoma Mimicking Early-Onset Nodular Panniculitis.
Shen G; Dong L; Zhang S
Am J Case Rep; 2016 Jun; 17():429-33. PubMed ID: 27342380
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
19. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib.
Fischer K; Aringer M; Steininger J; Heil J; Beissert S; Abraham S; Günther C
Br J Dermatol; 2022 Sep; 187(3):432-435. PubMed ID: 35318646
[No Abstract] [Full Text] [Related]
20. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
